Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Senescence, Frailty, and Mesenchymal Stem Cell Functionality in Chronic Kidney Disease: Effect of Senolytic Agents

Authors not listed

Mayo Clinic · 2016

Abstract

The study goal is to assess the effect of senescent cell clearance on senescence(definition) burden, physical ability or frailty, and adipose tissue-derived mesenchymal stem cell (MSC) functionality in patients with chronic kidney disease (CKD).

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-10-12 MST

Cite this

APA
Anonymous. (2016). Senescence, Frailty, and Mesenchymal Stem Cell Functionality in Chronic Kidney Disease: Effect of Senolytic Agents. <em>Mayo Clinic</em>. https://clinicaltrials.gov/study/NCT02848131
Vancouver
Anonymous. Senescence, Frailty, and Mesenchymal Stem Cell Functionality in Chronic Kidney Disease: Effect of Senolytic Agents. Mayo Clinic. 2016.
BibTeX
@misc{anon2016Senesc, title = {Senescence, Frailty, and Mesenchymal Stem Cell Functionality in Chronic Kidney Disease: Effect of Senolytic Agents}, author = {Anonymous}, journal = {Mayo Clinic}, year = {2016}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings